Residual Variants May Predict Relapse, Death in AML
Residual variants are associated with a higher risk of relapse and death among AML patients undergoing HSCT in first remission, a study suggests.
Diagnosis & Disease Information
Adverse Birth Outcomes More Common Among AYAs With Cancer During Pregnancy
Adolescent and young adult patients diagnosed with cancer during pregnancy have a higher risk of adverse birth outcomes, a study suggests.
Patterns of COVID-19 Vaccination in Cancer Patients Who Already Had COVID-19
Several factors influenced the likelihood of COVID-19 vaccination among patients with cancer who already had COVID-19, a new study suggests.
Infections Observed in Half of MM Patients Treated With Bispecific Antibodies
Infections are common among patients with relapsed/refractory multiple myeloma treated with bispecific antibodies, a study suggests.
Anti-GPRC5D CAR-T Therapy Elicits Responses After Anti-BCMA CAR Failure
Anti-GPRC5D CAR T-cell therapy can produce responses in patients with relapsed or refractory multiple myeloma, a phase 2 trial suggests.
FDA Panel Votes on Polivy Combo for First-Line Treatment of DLBCL
An FDA panel voted in favor of approving polatuzumab vedotin in combination with R-CHP for previously untreated DLBCL.
5 Factors That May Affect Multiple Myeloma Outcomes
What are some of the most important factors affecting outcomes in patients with multiple myeloma?
COVID-19 Sequelae in Cancer by Vaccination Status and Variant Era
COVID-19 vaccination may reduce the risk of COVID-19 sequelae in patients with cancer, according to researchers.
Cost of Cancer for AYAs Exceeds $250,000 Over a Lifetime
In the US, AYAs with cancer face high economic and human costs throughout their lifetime.
A Dedicated Clinic Decreases Time From Onset of Febrile Neutropenia to Treatment
A dedicated outpatient care clinic at an established cancer center decreased the time from febrile neutropenia onset to treatment.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...